Insight Molecular Diagnostics Inc. - 8-K Filing

Insight Molecular Diagnostics reports Q3 2026 revenue of $559,000 and provides update on FDA GraftAssureDx review process. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IMDX

Read the full article at SEC EDGAR

Part of the story KYNTRA BIO, INC. - 8-K Filing (3 articles)

More Regulatory news